Blurbs

Analysts’ Top Healthcare Picks: Steris (STE), Blueprint Medicines (BPMC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Steris (STEResearch Report) and Blueprint Medicines (BPMCResearch Report) with bullish sentiments.

Steris (STE)

JMP Securities analyst David Turkaly reiterated a Buy rating on Steris today and set a price target of $270.00. The company’s shares closed last Tuesday at $224.44.

According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 4.0% and a 46.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

Steris has an analyst consensus of Strong Buy, with a price target consensus of $252.00.

See today’s best-performing stocks on TipRanks >>

Blueprint Medicines (BPMC)

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Blueprint Medicines today and set a price target of $152.00. The company’s shares closed last Tuesday at $56.29.

According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.7% and a 34.7% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $81.00 average price target, implying a 62.0% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $115.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on STE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More